RCT: Active surveillance plus Enzalutamide monotherapy vs. active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer.

Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer – JAMA Oncology

Invited Commentary: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (free for a limited period)

Video criticizing the article: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad

Commentaries on Twitter

55% fatigue and 36% gynecomastia. In AS patients.

Why do we keep trying to escalate when the data CLEARLY say we should continue to de-escalate? https://t.co/LY1kD0jN65

— Chris Barbieri (@Chris_Barbieri1) June 17, 2022

The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. https://t.co/q9FrL14em1 #PCSM #GUCSM

— JAMA Oncology (@JAMAOnc) June 16, 2022